Toru Yoshimitsu
Director/Board Member chez OCATA THERAPEUTICS INC
Profil
Toru Yoshimitsu is currently a Director at Astellas Institute for Regenerative Medicine.
Previously, he worked as a Director at Astellas Pharma Europe Ltd.
from 2017 to 2020 and as a Director at Astellas Gene Therapies, Inc.
Postes actifs de Toru Yoshimitsu
| Sociétés | Poste | Début |
|---|---|---|
| OCATA THERAPEUTICS INC | Director/Board Member | - |
Anciens postes connus de Toru Yoshimitsu
| Sociétés | Poste | Fin |
|---|---|---|
Astellas Pharma Europe Ltd.
 Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Director/Board Member | 31/03/2020 |
| AUDENTES THERAPEUTICS, INC. | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Astellas Institute for Regenerative Medicine
 Astellas Institute for Regenerative Medicine Pharmaceuticals: MajorHealth Technology Astellas Institute for Regenerative Medicine engages in the development and commercialization of human pluripotent stem cell technology in the field of regenerative medicine. The company also have a preclinical development pipeline in areas outside of ophthalmology, including; autoimmune diseases, inflammatory diseases, and wound healing. The company was founded on May 18, 2000 and is headquartered in Marlborough, MA. | Health Technology |
Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd. Pharmaceuticals: MajorHealth Technology Astellas Pharma Europe Ltd. engages in the development and sale of pharmaceutical products. The company is headquartered in Addlestone, the United Kingdom. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
